Inflammaging and Immunosenescence: Mechanisms and Link

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 4213

Special Issue Editor


E-Mail Website
Guest Editor
National Taiwan University Hospital, Taipei, Taiwan
Interests: inflammaging; advanced glycation endproducts; immunosenescence

Special Issue Information

Dear Colleagues,

Inflammaging represents chronic, sterile, low-grade inflammation during aging and in age-related diseases. These age-related diseases may include osteoarthritis, sarcopenia, polyarthritis, metabolic syndrome, diabetic mellitus, neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, cardiovascular disease, cancer, chronic obstructive pulmonary disease, and chronic kidney disease. The contribution of inflammaging during aging is gradually widely known, but in age-related diseases, this puzzle must be solved.

Another character of aging and age-related disease is immunosenescence, or aging immunity. Immunosenescence has been widely studied in cancer, chronic kidney disease, and autoimmune disease. However, the role of immunosenescence in a other age-related disease remained to be elucidated.

Authors are invited to submit manuscripts discussing inflammaging or immunosenescence, focusing either on the basic or translational aspects, particularly related to autoimmunity and age-related diseases. The Special Issue welcomes up-to-date comprehensive reviews and research articles. Clinical studies combined with molecular research, if relevant, as well as computational modeling, are also welcome.

Dr. Chieh Yu Shen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammaging
  • immunosenescence
  • autoimmune disease
  • age-related disease
  • aging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 1896 KiB  
Article
Effect of Menopausal Hormone Therapy on Cellular Immunity Parameters and Cytokine Profile
by Marina Averyanova, Svetlana Yureneva, Viktoriia Kiseleva, Oksana Yakushevskaya, Marina Iskusnykh, Anna Pavlova, Andrey Elchaninov, Timur Fatkhudinov, Natalia Mikhanoshina, Tatiana Ivanets, Valentina Vtorushina, Lyubov Krechetova, Polina Vishnyakova and Gennady Sukhikh
Biomedicines 2024, 12(8), 1892; https://doi.org/10.3390/biomedicines12081892 - 19 Aug 2024
Viewed by 741
Abstract
Background: A woman’s entry into the menopause period is associated with a number of changes in the body, including those related to the immune system. Immune aging is a consequence of age-related changes in the function of immune cells and the composition of [...] Read more.
Background: A woman’s entry into the menopause period is associated with a number of changes in the body, including those related to the immune system. Immune aging is a consequence of age-related changes in the function of immune cells and the composition of their subpopulations. Menopausal hormone therapy (MHT) is thought to partially neutralize the negative effects of aging on the immune system. Objective: We aimed to evaluate the effect of oral and transdermal MHT on cellular immunity parameters and cytokine profile in menopausal women. Methods: Fifty peri- and early postmenopausal women were included. Immune parameters were assessed by flow cytometry and multiplex analysis. Results: We showed that different routes of MHT administration led to significant changes in monocyte phenotype and a decrease in monocyte chemoattractant protein-1 (MCP-1) level in menopausal patients. In addition, oral MHT resulted in a significant increase in NK and B cells. A significant increase in the number of T-helper cells was observed with transdermal MHT. In addition, oral MHT resulted in a significant decrease in IL-1β level. Conclusions: We have demonstrated for the first time that oral therapy, in contrast to transdermal therapy, has a more pronounced effect on specific immune subpopulations of blood cells in menopausal women. This effect is likely to be responsible for its anti-aging properties in the context of immune aging as well as its protective effects in infectious diseases. Perhaps testing blood immune parameters or assessing immune status before prescribing MHT could become a routine step in clinical practice before choosing a patient management strategy. Full article
(This article belongs to the Special Issue Inflammaging and Immunosenescence: Mechanisms and Link)
Show Figures

Figure 1

Review

Jump to: Research

20 pages, 695 KiB  
Review
Understanding the Complex Dynamics of Immunosenescence in Multiple Sclerosis: From Pathogenesis to Treatment
by Monica Neațu, Ana Hera-Drăguț, Iulia Ioniță, Ana Jugurt, Eugenia Irene Davidescu and Bogdan Ovidiu Popescu
Biomedicines 2024, 12(8), 1890; https://doi.org/10.3390/biomedicines12081890 - 19 Aug 2024
Viewed by 831
Abstract
Immunosenescence, the gradual deterioration of immune function with age, holds profound implications for our understanding and management of multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system. Traditionally diagnosed in young adults, advancements in disease-modifying therapies and increased life expectancy [...] Read more.
Immunosenescence, the gradual deterioration of immune function with age, holds profound implications for our understanding and management of multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system. Traditionally diagnosed in young adults, advancements in disease-modifying therapies and increased life expectancy have led to a growing number of older individuals with MS. This demographic shift underscores the need for a deeper investigation into how age-related alterations in immune function shape the course of MS, influencing disease progression, treatment effectiveness, and overall patient outcomes. Age-related immunosenescence involves changes such as shifts in cytokine profiles, the accumulation of senescent immune cells, and compromised immune surveillance, collectively contributing to a state known as “inflammaging”. In the context of MS, these immunological changes disturb the intricate balance between inflammatory and regulatory responses, thereby impacting mechanisms of central immune tolerance and peripheral regulation. This paper stands out by combining the most recent advancements in immunosenescence with both pathophysiological and treatment perspectives on multiple sclerosis, offering a cohesive and accessible discussion that bridges theory and practice, while also introducing novel insights into underexplored concepts such as therapy discontinuation and the latest senolytic, neuroprotective, and remyelination therapies. Enhancing our understanding of these complexities will guide tailored approaches to MS management, ultimately improving clinical outcomes for affected individuals. Full article
(This article belongs to the Special Issue Inflammaging and Immunosenescence: Mechanisms and Link)
Show Figures

Figure 1

23 pages, 4471 KiB  
Review
Advanced Glycation End-Products Acting as Immunomodulators for Chronic Inflammation, Inflammaging and Carcinogenesis in Patients with Diabetes and Immune-Related Diseases
by Chieh-Yu Shen, Cheng-Hsun Lu, Chiao-Feng Cheng, Ko-Jen Li, Yu-Min Kuo, Cheng-Han Wu, Chin-Hsiu Liu, Song-Chou Hsieh, Chang-Youh Tsai and Chia-Li Yu
Biomedicines 2024, 12(8), 1699; https://doi.org/10.3390/biomedicines12081699 - 31 Jul 2024
Viewed by 1174
Abstract
Increased production of advanced glycation end products (AGEs) among reducing sugars (glucose, fructose, galactose, or ribose) and amino acids/proteins via non-enzymatic Maillard reaction can be found in lifestyle-related disease (LSRD), metabolic syndrome (MetS), and obesity and immune-related diseases. Increased serum levels of AGEs [...] Read more.
Increased production of advanced glycation end products (AGEs) among reducing sugars (glucose, fructose, galactose, or ribose) and amino acids/proteins via non-enzymatic Maillard reaction can be found in lifestyle-related disease (LSRD), metabolic syndrome (MetS), and obesity and immune-related diseases. Increased serum levels of AGEs may induce aging, diabetic complications, cardiovascular diseases (CVD), neurodegenerative diseases (NDD), cancer, and inflamm-aging (inflammation with immunosenescence). The Maillard reaction can also occur among reducing sugars and lipoproteins or DNAs to alter their structure and induce immunogenicity/genotoxicity for carcinogenesis. AGEs, as danger-associated molecular pattern molecules (DAMPs), operate via binding to receptor for AGE (RAGE) or other scavenger receptors on cell surface to activate PI3K-Akt-, P38-MAPK-, ERK1/2-JNK-, and MyD88-induced NF-κB signaling pathways to mediate various pathological effects. Recently, the concept of “inflamm-aging” became more defined, and we have unveiled some interesting findings in relation to it. The purpose of the present review is to dissect the potential molecular basis of inflamm-aging in patients with diabetes and immune-mediated diseases caused by different AGEs. Full article
(This article belongs to the Special Issue Inflammaging and Immunosenescence: Mechanisms and Link)
Show Figures

Figure 1

Back to TopTop